Literature DB >> 23233000

Resistin expression correlates with steatohepatitis in morbidly obese patients.

Claire R Edwards1, A Katharine Hindle, Patricia S Latham, Sidney W Fu, Fred J Brody.   

Abstract

BACKGROUND: Morbidly obese patients are at risk for nonalcoholic steatohepatitis (NASH) even in the absence of risk factors for liver disease. Unfortunately, NASH is usually not clinically evident, and a definitive, noninvasive test for NASH does not exist. Resistin, a cytokine originating from adipose tissue, is involved in insulin resistance and also initiates proinflammatory signaling from hepatic stellate cells. This study explores the relationship between resistin expression and liver pathology in bariatric surgery patients.
METHODS: Blood samples from 30 patients undergoing bariatric surgery were collected. Total RNA was extracted and cDNA was synthesized. Quantitative RT-PCR was used to quantify relative gene expression using 18s rRNA gene as an internal control. Wedge liver biopsies from these patients were sectioned and stained. Based on a previously published scoring method, biopsies were assigned an overall NASH severity score and subscores for steatosis, inflammation, and fibrosis. Results were analyzed by using Student's t test.
RESULTS: Resistin mRNA levels ranged from 0.5 to 9.7. A group of five patients with very high resistin expression (>4) was identified. These patients had a significantly higher average NASH score compared with the rest of the group (7.9 vs. 4.48, p = 0.019). Steatosis and inflammation scores were significantly higher in the high-resistin group (p < 0.05 for both comparisons). There also was a trend toward higher fibrosis score in this group, which approached statistical significance (p = 0.051).
CONCLUSIONS: In morbidly obese patients, high resistin expression in serum is associated with hepatic steatosis, inflammation, and fibrosis. The development of elevated resistin expression may represent a link between obesity and the onset of steatohepatitis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23233000     DOI: 10.1007/s00464-012-2603-y

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  22 in total

1.  Serum resistin and hepatic fat content in nondiabetic individuals.

Authors:  Gianluca Perseghin; Guido Lattuada; Francesco De Cobelli; Georgia Ntali; Antonio Esposito; Agata Burska; Elena Belloni; Tamara Canu; Francesca Ragogna; Paola Scifo; Alessandro Del Maschio; Livio Luzi
Journal:  J Clin Endocrinol Metab       Date:  2006-09-12       Impact factor: 5.958

Review 2.  Hepatic complications of obesity.

Authors:  Anna Mae Diehl
Journal:  Gastroenterol Clin North Am       Date:  2010-03       Impact factor: 3.806

3.  Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome.

Authors:  Samer G Mattar; Laura M Velcu; Mordechai Rabinovitz; A J Demetris; A M Krasinskas; Emma Barinas-Mitchell; George M Eid; Ramesh Ramanathan; Debra S Taylor; Philip R Schauer
Journal:  Ann Surg       Date:  2005-10       Impact factor: 12.969

4.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

Review 5.  Recent advances in nonalcoholic fatty liver disease.

Authors:  Onpan Cheung; Arun J Sanyal
Journal:  Curr Opin Gastroenterol       Date:  2010-05       Impact factor: 3.287

Review 6.  Resistin.

Authors:  Philip G McTernan; Christine M Kusminski; Sudhesh Kumar
Journal:  Curr Opin Lipidol       Date:  2006-04       Impact factor: 4.776

7.  Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels.

Authors:  Ling-Ling Jiang; Lin Li; Xiao-Fei Hong; You-Ming Li; Bing-Ling Zhang
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-06       Impact factor: 2.566

Review 8.  Toll-like receptors and their role in gastrointestinal disease.

Authors:  Adam G Testro; Kumar Visvanathan
Journal:  J Gastroenterol Hepatol       Date:  2009-06       Impact factor: 4.029

9.  A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).

Authors:  Zobair M Younossi; Mohammed Jarrar; Clare Nugent; Manpreet Randhawa; Mariam Afendy; Maria Stepanova; Nila Rafiq; Zachary Goodman; Vikas Chandhoke; Ancha Baranova
Journal:  Obes Surg       Date:  2008-05-24       Impact factor: 4.129

10.  Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis.

Authors:  John G Kral; Swan N Thung; Simon Biron; Frederic-Simon Hould; Stefane Lebel; Simon Marceau; Serge Simard; Picard Marceau
Journal:  Surgery       Date:  2004-01       Impact factor: 3.982

View more
  3 in total

1.  Saturated fat and cholesterol are critical to inducing murine metabolic syndrome with robust nonalcoholic steatohepatitis.

Authors:  Jamie E Mells; Ping P Fu; Pradeep Kumar; Tekla Smith; Saul J Karpen; Frank A Anania
Journal:  J Nutr Biochem       Date:  2014-12-06       Impact factor: 6.048

Review 2.  The immune remodel: Weight loss-mediated inflammatory changes to obesity.

Authors:  Charles L Phillips; Bernadette E Grayson
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-19

3.  Resistin mediates the hepatic stellate cell phenotype.

Authors:  Zhi-Xia Dong; Lin Su; Joanne Brymora; Claire Bird; Qing Xie; Jacob George; Jian-Hua Wang
Journal:  World J Gastroenterol       Date:  2013-07-28       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.